论文部分内容阅读
目的 探讨GM1 对脑卒中患者的脑保护作用。方法 将脑卒中患者分为常规治疗组及加用GM1 治疗组 ,以RIA法动态监测患者的血清神经元特异性烯醇化酶 (NSE)。结果 脑卒中患者两组血清NSE均于病后 48h～ 9d较对照组明显升高 (P <0 0 5 ,P <0 0 1 ) ,且均在病程 3～ 4d达高峰 ,随后逐渐下降 ;常规治疗组血清NSE在病后 1 0～ 1 4d恢复正常 ,而加用GM1 治疗组血清NSE则在 3～ 1 4d较常规治疗组相应病期低 (P <0 0 5 ,P <0 0 0 1 ) ,且提前降至正常。结论 动态监测血清NSE有助于观察脑卒中患者病情的变化 ;GM1 可能通过减轻神经元的继发损伤 ,降低血清NSE ,从而起到脑保护作用。
Objective To investigate the protective effects of GM1 on stroke patients. Methods Stroke patients were divided into routine treatment group and GM1 treatment group. Serum neuron-specific enolase (NSE) was detected by RIA. Results Serum NSE levels in both groups were significantly higher than those in the control group at 48h ~ 9d after stroke (P <0.05, P <0.01), and all reached the peak at 3 ~ 4d and then gradually decreased. Conventional Serum NSE in the treatment group returned to normal after 10 ~ 14 days, while serum NSE in the GM1 group was lower than that in the conventional treatment group at 3 ~ 14 days (P <0.05, P <0.01) ), And dropped to normal earlier. Conclusion Dynamic monitoring of serum NSE can help to observe the changes of stroke patients. GM1 may play a neuroprotective role by reducing neuronal secondary damage and serum NSE.